Highlights

  • OncoSil Medical shares rose 6.19% to AUD 0.52 on 28 April 2026, as investors reacted positively to Q3 FY26 Update.
  • Q3 FY26 dose sales increased 60% year-on-year, reflecting expanding clinical adoption.
  • Revenue grew 49% compared to the prior corresponding period.
  • Early clinical data in Türkiye showed 83% surgical conversion rate in treated patients.
  • $8 million Capital raise completed, with cash position at $9.3 million at quarter end.
  • Annualised cost savings of $3.4 million to $3.9 million targeted from FY27.

OncoSil Medical Ltd (ASX:OSL) shares advanced 6.19% to AUD 0.52 during the afternoon session on 28 April 2026, following the release of its quarterly activities and Cash Flow report for the period ended 31 March 2026. Despite the stock remaining down 74.12% over the past year, the latest update highlights improving operational momentum, growing clinical adoption, and progress across key strategic initiatives, which appear to be supporting today’s share price movement.

OncoSil Medical is a medical device company focused on interventional oncology, specifically targeting patients with unresectable locally advanced pancreatic cancer. Its proprietary OncoSil device enables the targeted delivery of radiation directly into tumours using phosphorous-32 microparticles, in combination with chemotherapy. The therapy is designed to improve local disease control while limiting damage to surrounding healthy tissue, addressing a condition where treatment Options remain limited and outcomes are often poor.

Strong Growth in Dose Sales and Commercial Activity

During Q3 FY26, OncoSil Medical reported continued expansion in its commercial operations, with dose unit sales increasing by 60% compared to the prior corresponding period. This growth reflects increasing clinical adoption of the OncoSil device across key markets.

Revenue for the quarter rose 49% year-on-year, indicating that increased utilisation is translating into financial performance. Additionally, the number of commercially active treatment centres grew by 56% to 28 sites, demonstrating broader geographic penetration and growing physician engagement.

The expansion in treatment centres is a key component of the company’s commercial strategy, as it supports both increased patient access and greater utilisation of the technology across established healthcare networks.

Clinical Progress and Trial Milestones Support Development Pathway

The company achieved several clinical milestones during the quarter, including the completion of Last Patient, Last Visit (LPLV) in the TRIPP-FFX trial. This multi-centre study, involving 88 patients across 15 sites in Europe and Australia, is evaluating the OncoSil device in combination with FOLFIRINOX chemotherapy.

With patient treatment and follow-up now complete, the company will proceed to final data analysis, with results expected in Q4 FY26. A regulatory submission is planned for the second half of calendar year 2026, which could support expansion of approved treatment indications.

In parallel, the PANCOSIL investigator-initiated study is progressing toward regulatory submission, with patient recruitment completed and preliminary data already presented at a major clinical congress. This study is evaluating a percutaneous delivery approach that may expand the pool of treating clinicians and increase accessibility.

Early Clinical Data Highlights Treatment Potential

During the quarter, OncoSil reported early clinical outcomes from initial commercial use of its device in Türkiye. Six patients with locally advanced pancreatic cancer were treated using OncoSil in combination with chemotherapy.

The results showed one complete response and four partial responses, with five out of six patients (83%) subsequently undergoing successful surgical resection with curative intent. This outcome exceeds typical resection rates reported for this patient group and highlights the potential of the therapy to convert previously inoperable cases into surgical candidates.

These findings contribute to the growing body of real-world clinical evidence supporting the use of OncoSil and may play a role in expanding adoption among clinicians.

Published Study Demonstrates Survival and Disease Control Benefits

A peer-reviewed study published during the quarter compared outcomes for patients treated with OncoSil plus chemotherapy against those receiving chemotherapy alone. The analysis included 104 patients and demonstrated improved clinical outcomes for the combination therapy group.

Key findings included a 6.2-month improvement in overall survival within 30 months, a 5.5-month increase in local progression-free survival, and higher rates of tumour downstaging and surgical resection. Specifically, resection rates were 28.6% for the combination therapy group compared to 12.1% for chemotherapy alone.

The study also reported a favourable safety profile, with no serious procedure-related adverse events observed. These results reinforce the potential role of OncoSil in enhancing treatment outcomes for patients with limited therapeutic Options.

Expansion Across European Treatment Centres

OncoSil continued to expand its presence across Europe during the quarter, with new treatment sites initiated in Germany and Türkiye. In Germany, treatments commenced at Vivantes Neukölln Hospital in Berlin and Universitätsklinikum Augsburg, reflecting increasing adoption in one of Europe’s largest healthcare markets.

In Türkiye, the company expanded into Acibadem Maslak Hospital, part of a major private healthcare network. These developments highlight ongoing growth in clinical utilisation and support the company’s strategy to build momentum ahead of broader regulatory and commercial expansion.

Germany Trial Represents Key Market Opportunity

The company is preparing for the anticipated commencement of the fully funded G-BA trial in Germany, expected in Q4 FY26. Germany represents a significant market, with approximately 22,587 new pancreatic cancer cases diagnosed annually.

The trial is a key component of the reimbursement pathway and is expected to support broader adoption of the OncoSil device within the German healthcare system. High-Volume pancreatic cancer centres are expected to play a central role in both trial participation and future commercial uptake.

OncoSil estimates that the trial could generate approximately $47.1 million in value over its duration, reflecting the potential impact of successful market access in Germany.

Cost Optimisation and Operational Efficiency Initiatives

During the quarter, OncoSil implemented a series of strategic initiatives aimed at reducing its cost base and improving operational efficiency. The company expects to achieve annualised cost savings of between $3.4 million and $3.9 million from FY27 onwards.

These savings are expected to result from streamlined corporate functions, completion of major Clinical Trials, and the conclusion of Capital investment in its new Manufacturing Facility. The initiatives are intended to reduce cash burn and support a more Capital-efficient operating model.

Additionally, the appointment of a new Global Head of Manufacturing and Operations reflects a focus on strengthening operational execution, with remuneration structured entirely in Equity.

Manufacturing and Financial Position

The company’s new Manufacturing Facility in Macquarie Park is progressing toward operational readiness, with final validation and regulatory processes underway. The Facility is expected to be operational in 1H FY27 and is anticipated to reduce Cost of Goods Sold, enhance production capacity, and improve Supply chain resilience.

From a financial perspective, OncoSil reported a cash balance of $9.3 million as at 31 March 2026, following an $8 million Capital raise during the quarter. Customer receipts increased 158% year-on-year to $0.6 million for the quarter and 177% to $1.7 million for the nine-month period.

Operating cash outflows decreased by $2.1 million compared to the prior quarter, supported by cost management initiatives and the receipt of a $1.8 million R&D tax incentive.

What This Means for Investors?

OncoSil Medical’s Q3 FY26 update reflects continued progress across commercial, clinical, and operational fronts. Growth in dose sales, Revenue, and treatment centres indicates increasing adoption, while clinical milestones and published data support the therapy’s potential.

At the same time, the company is advancing key regulatory pathways and implementing cost optimisation measures aimed at improving financial efficiency. The strengthening cash position and upcoming milestones, including trial results and regulatory submissions, remain central to its outlook.

Today’s share price movement appears to reflect these developments, with investors responding to a combination of operational growth and forward-looking catalysts, despite the stock’s longer-term decline.